| Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer J Stebbing, AJ Bullock Clinical Cancer Research 30 (10), 2005-2007, 2024 | | 2024 |
| CCR5 and CCL5 in metastatic colorectal cancer BL Schlechter, J Stebbing Journal for ImmunoTherapy of Cancer 12 (5), e008722, 2024 | | 2024 |
| An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma Z Du, X Han, L Zhu, L Li, L Castellano, J Stebbing, L Peng, Z Wang BMC Medical Genomics 17 (1), 86, 2024 | | 2024 |
| Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study RC Allsopp, Q Guo, K Page, S Bhagani, A Kasim, P Badman, L Kenny, ... Breast Cancer Research and Treatment, 1-9, 2024 | | 2024 |
| Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer JA Shaw, K Page, E Wren, EC de Bruin, E Kalashnikova, R Hastings, ... JCO Precision Oncology 8, e2300456, 2024 | | 2024 |
| The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS I Grigoropoulos, G Tsioulos, A Kastrissianakis, S Shapira, O Green, ... Respiratory Research 25 (1), 151, 2024 | | 2024 |
| Kinome‐Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma V Vella, A Ditsiou, A Chalari, M Eravci, SK Wooller, T Gagliano, C Bani, ... Advanced Science, 2306027, 2024 | | 2024 |
| A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome TC Hammond, MA Purbhoo, S Kadel, J Ritz, S Nikiforow, H Daley, ... Nature Communications 15 (1), 974, 2024 | 1 | 2024 |
| Genes and Race in Colon Cancer J Stebbing, BL Schlechter Journal of Clinical Oncology 42 (4), 369-372, 2024 | 1 | 2024 |
| Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma P Wang, Z Wang, Y Lin, L Castellano, J Stebbing, L Zhu, L Peng Molecular biotechnology 66 (2), 332-353, 2024 | 1 | 2024 |
| LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC). L Torres-Gonzalez, F Battaglin, S Soni, Y Baca, J Xiu, P Walker, JH Lo, ... Journal of Clinical Oncology 42 (3_suppl), 172-172, 2024 | | 2024 |
| A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease M Mato Prado, JR Puik, L Castellano, E López-Jiménez, DSK Liu, ... Experimental hematology & oncology 12 (1), 101, 2023 | | 2023 |
| A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing data Z Du, T Zhang, Y Lin, G Dong, A Li, Z Wang, Y Zhang, G Giamas, ... Heliyon 9 (11), 2023 | | 2023 |
| The mutational landscape of the adult healthy parous and nulliparous human breast B Cereser, A Yiu, N Tabassum, L Del Bel Belluz, S Zagorac, KRZ Ancheta, ... Nature Communications 14 (1), 5136, 2023 | 1 | 2023 |
| PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ... Molecular cancer 22 (1), 138, 2023 | 135 | 2023 |
| Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 … J Stebbing, Y Baranau, V Baryash, V Moiseyenko, D Boliukh, N Antone, ... BioDrugs 37 (3), 433-440, 2023 | 1 | 2023 |
| Kinome-wide synthetic lethal screen identifies PANK4 as modulator of resistance in glioblastoma V Vella, A Ditsiou, A Chalari, M Eravci, SK Wooler, T Gagliano, C Bani, ... | | 2023 |
| Comparison of phenomics and cfDNA in a large breast screening population: The Breast Screening and Monitoring Study (BSMS) J Stebbing, PG Takis, CJ Sands, L Maslen, MR Lewis, K Gleason, K Page, ... Oncogene 42 (11), 825-832, 2023 | 3 | 2023 |
| A pyroptosis‐related lncRNA signature in bladder cancer P Wang, Z Wang, L Zhu, Y Sun, L Castellano, J Stebbing, Z Yu, L Peng Cancer medicine 12 (5), 6348-6364, 2023 | 4 | 2023 |
| Design and reporting of phase III oncology trials with prospective biomarker validation F Liang, L Peng, Z Wu, G Giamas, J Stebbing JNCI: Journal of the National Cancer Institute 115 (2), 174-180, 2023 | 2 | 2023 |
